Home » Investors » Management Team

Management Team

Alan Tuchman, M.D.Acting Chief Medical Officer
Alan Tuchman, MD, MBA (FAAN) is Clinical Professor of Neurology at New York Medical College and the author of over 30 scientific papers and book chapters. He is currently in the private practice of Neurology in Manhattan. He served as Senior Vice President and Chief Medical Officer of Oncolytics Biotech Inc. from 2012-2017 and consults to a number of biotechnology and investment firms. He was as a partner of Xmark Opportunity Partners from 2002 – 2007 and as Executive Chairman of Neurophysics, Inc. from 2003 – 2008. He was the President of the Epilepsy Society of Southern New York from 1992 -1996 as well as Vice Dean for Clinical Affairs at New York Medical College from 1995-1997.

Dr. Tuchman received his MD degree from the University of Cincinnati, College of Medicine, and completed his Neurology Residency at the Mt Sinai School of Medicine. Dr. Tuchman received his MBA from Columbia University.
Daniel Alkon, M.D.President & Chief Scientific Officer
Dr. Alkon has served as President and Chief Scientific Officer of Neurotrope since September 2016. A leader in the field, Dr. Alkon comes to Neurotrope after 30 years directing programs on the molecular basis of associative memory at the National Neurologic Institute of NIH, and another 15 years as the Founding Scientific Director of the Blanchette Rockefeller. Neuroscience Institute where he and his team developed neurorestorative therapeutics for degenerative disorders of the central nervous system. He also served as the Toyota Chair of Neurodegenerative Diseases and Professor of Neurology at West Virginia University before joining Neurotrope.

An internationally recognized pioneer in research on brain-based neural networks, the molecular basis of memory, and degenerative brain disorders, he has authored hundreds of scientific articles as well as several books, including Memory Traces in the Brain by Cambridge University Press, and the popular book Memory’s Voice by Harper Collins.

Dr. Alkon received his B.A. from the University of Pennsylvania, and his M.D. at Cornell University, after which he interned at the Mt Sinai Hospital in New York.
Robert WeinsteinChief Financial Officer
Mr. Weinstein joined the Company in June 2013 as its acting Chief Financial Officer. He has extensive accounting and finance experience, spanning more than 30 years, as a public accountant, investment banker, healthcare private equity fund principal and chief financial officer.

Mr. Weinstein served as an independent consultant for several healthcare companies in the pharmaceutical and biotechnology industries. Prior to joining Neurotrope, he was CFO at Green Energy Management Services Holdings, Inc., a publicly-traded energy consulting company, as well as CFO at Xcorporeal, Inc., a publicly-traded, development-stage medical device company which was sold to Fresenius Medical USA, the largest provider of dialysis equipment and services worldwide.

Mr. Weinstein received his MBA degree in finance and international business from the University of Chicago Graduate School of Business, is a Certified Public Accountant (inactive), and received his BS degree in accounting from the State University of New York at Albany.
Elaine GrenierExecutive Director, Clinical Ops
Ms. Grenier has more than 25 years of experience in the pharmaceutical industry, with management responsibility for clinical trials in oncology, cardiovascular, central nervous system and genetic disease indications. Ms. Grenier participated in globalization of clinical development processes for a prominent pharmaceutical company to achieve uniform research standards across all global subsidiaries, with sensitivity to cultural and organizational differences. Ms. Grenier has provided management and leadership of multiple functional areas for integrated, comprehensive project oversight for US and international research programs.

Ms. Grenier attended the University of Maryland.

Investor Contact Information

Company

Synaptogenix, Inc.
1185 Avenue of the Americas,
3rd Floor
New York, NY 10036
(973) 242-0005

Investor Relations

Hayden IR
T: 646-536-7331
brett@haydenir.com